AR and prostate cancer: Rhiz functions to re‐sensitize AR‐V7‐positive prostate cancer cells to enzalutamide, while SINT1 inhibited prostate cancer cell growth by binding to the activation function‐1 (AF‐1) region in the NTD of AR.